Over the past year, Shield AI's valuation has soared by 140%, driven by securing a key contract as the software provider for Anduril's Fury fighter jet used by the U.S. Air Force.

From combating doomscrolling to advancing humanoid robot training, these 16 startups emerged as the most compelling from a crowded YC W26 cohort.

Recent headlines in venture capital highlight a trend toward larger investment rounds amidst rising valuations and mega funds. Smaller and more modest seed rounds are becoming less common, as confirmed by Crunchbase data on U.S. seed funding. From 2024 to 2025, deal counts and total funding for smaller seed rounds from $200,000 to under $5 million declined by roughly 20%, while the largest seed deals of $10 million and above grew significantly.

This bifurcation splits the market between elite AI startups attracting substantial Series A funding from major firms, and other companies facing tougher competition. In response, some seed funds are altering strategies to preserve more capital for promising startups and to invest at earlier stages, sometimes prior to product-market fit.

The share of seed deals under $5 million dropped from 93% in 2018 to 75% in 2025, while those above $10 million rose from 2% to 9%. Total U.S. seed funding reached $19.4 billion in 2025, largely driven by large rounds, including a record $2 billion seed round by Thinking Machines Lab. Outlier rounds over $50 million surged over 300% in 2025, reflecting AI’s influence on early-stage investment dynamics.

Seed funding is not declining but evolving, with larger rounds becoming the norm for top-tier startups, while smaller funds continue to play a vital role in nurturing emerging companies in a tough market environment.

Many users have tried AI tools without seeing much benefit, but my real-world experience tells a different story. Over the past six months, I transformed my engineering team to prioritize AI-first workflows, significantly accelerating our development speed. Despite reducing our team size from 36 to 30, our output increased by 170%, roughly doubling our efficiency.

We shifted from lengthy design phases to rapid prototyping, using AI to quickly turn ideas into viable products. This approach not only sped up development but also enhanced product quality and customer satisfaction by integrating AI-powered testing directly into our workflows. Our QA team evolved from traditional testers into system architects who build AI agents to automate acceptance tests, fundamentally changing how we validate and ensure software quality.

On a structural level, software development has inverted from a linear assembly line to a control-tower model, where humans set intent and validate outcomes, while AI handles execution efficiently. Our engineers now operate at a higher abstraction level, focusing on orchestrating AI workflows rather than traditional coding, marking a new era where strategic thinking and AI collaboration drive innovation.

Physical Intelligence is currently negotiating a funding round that could inject an additional $1 billion into the company, potentially doubling its valuation from $5.6 billion in just four months.

We asked nearly a dozen venture capitalists to share which startups from Y Combinator's W26 batch are generating the most buzz among investors.

As generative AI becomes essential in workplaces, enterprises face the 'shadow AI' issue—unsanctioned autonomous AI agents on personal infrastructure disrupting governance and security. Kilo, innovator in multi-model cloud AI coding environments, has introduced KiloClaw for Organizations and KiloClaw Chat, enabling enterprises to gain robust control, visibility, and governance over AI agents used by employees.

The rise of KiloClaw comes amid concerns of unmanaged AI workflows running on personal servers without audit logs or credential management, sparking security risks and blanket bans. KiloClaw aims to bring these autonomous agents under centralized organizational control, with features like identity and secrets management, centralized billing, and admin controls enforcing policies on AI model use.

Technologically, Kilo uses a 'Swiss cheese' reliability approach for mission-critical task completion despite operational interruptions, while also enhancing user experience through KiloClaw Chat — eliminating complexities of setting up communication channels for agents.

A novel governance model introduces employee 'bot accounts' that limit agent permissions to scoped, read-only access, reducing risks of data leaks. Kilo's open-source codebase alleviates fears of black-box algorithms and proprietary data exploitation.

Available now under a usage-based pricing model, KiloClaw invites organizations to adopt scalable AI agent adoption safely and efficiently, marking an important step toward secure enterprise AI deployments.

OpenAI has secured an unprecedented $122 billion in a private funding round, pushing its valuation to $852 billion. Major investors include Amazon, Nvidia, and SoftBank, underscoring strong industry backing as the company prepares for a potential IPO as soon as 2026. Despite generating around $2 billion monthly from ChatGPT subscriptions and enterprise agreements, OpenAI remains unprofitable, grappling with significant costs related to computing infrastructure and talent acquisition. The fresh capital is aimed at scaling more advanced AI models capable of autonomous operations in business. While some analysts view investments from technology giants as a competitive edge, others worry about the vast compute expenses delaying profitability. Comparisons to the late 1990s dot-com surge highlight skepticism about the current AI investment frenzy. Meanwhile, concerns over the operational security of competitors like Anthropic arise following recent leaks, and reviews of AI product monetization grow cautious after GitHub Copilot incident stirred developer backlash. Overall, OpenAI leads the AI race but faces the challenge of converting massive investment into sustainable profits.

Many tech visionaries predict AI will revolutionize medicine, potentially doubling human lifespans or curing all diseases within a decade. But while AI excels at designing molecules and accelerating early drug discovery, it can’t yet master the complexity of human biology or guarantee safety in clinical trials. The pharmaceutical industry still faces high clinical failure rates, despite AI’s advances. However, AI is transforming the preclinical phase by making drug discovery faster and producing higher quality candidates, with some drugs showing promising Phase IIa results. The next step is developing integrated AI systems to autonomously design and validate drugs. Though AI won’t erase all diseases imminently, it’s accelerating and improving medicine development, promising faster, cheaper, and more effective treatments in the near future.

Forget perks like nap pods and slippers — AI startups are attracting fresh tech talent with substantial cash offers, including salaries up to $400,000 and generous bonus packages for new graduates.